Endo bets up to $221M on NuPathe and its migraine patch

Endo Health Solutions ($ENDP) is extending its makeover with a bolt-on deal, trading $105 million up front for NuPathe ($PATH) to get its hands on the migraine patch Zecuity. Under the deal, Endo will fork over another $79 million if the patch's sales cross $100 million a year and another $37 million if they clear $300 million. NuPathe won FDA approval for Zecuity in January, and Endo said it plans to launch the sumatriptan-delivering patch in the first half of next year. The deal comes a month after Endo announced its plans to spend $1.6 billion for Canada's Paladin Labs, kicking off its effort to refocus on specialty pharmaceuticals. More

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.